NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine

TORONTO and HAIFA, Israel, April 19, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, was invited to present on "Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach" at the Exosomes of Europe conference in London in June, 2024.

Dr. Shaltiel joins a prestigious lineup of speakers presenting applications of exosomes, including representatives from leading exosome companies such as Abbvie, Evox Therapeutics and Capricor Therapeutics, as well as senior-level executives in the field. As a pioneer and leader in this field, Dr. Shaltiel is well-positioned to provide perspective on exploiting advances in exosomes for drug delivery. NurExone is developing a first exosome-loaded nanodrug, ExoPTEN, for patients who suffer acute Spinal Cord Injuries.

Exosomes Europe is a premier event that brings together experts from academia and industry to discuss new data and case studies on advancing exosome products from the clinical stage to commercialization. The conference will take place on June 5-6, 2024, in London, England. To learn more about the summit and to register, please visit the Conference Website.

About NurExone Biologic Inc.

NurExone Biologic Inc. is a TSXV listed pharmaceutical Company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications.

For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.

For more information, please contact:

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: [phone]
Email: [e-mail]

Thesis Capital Inc.
Investment Relation - Canada
Phone: [phone]
Email: [e-mail]

Dr. Eva Reuter
Investment Relation - Germany
Phone: [phone]
Email: [e-mail]